Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Forx Therapeutics AG has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner within 1 distinct art unit. This represents a very focused prosecution effort, typical for specialized biotechnology firms targeting a specific therapeutic area. The concentration in 1 distinct art unit indicates that the company's current patent activity is technically specialized within the biotech sector.
The busiest examiner, YOO, SUN JAE, is responsible for the 1 pending office action. Because there is only 1 distinct examiner and 1 distinct art unit involved, the company's current USPTO interaction is centralized. The immediate development of the company's patent portfolio in the biotech sector is dependent on the resolution of this 1 pending office action. Practitioners should focus on the specific examiner's history and the standards of the 1 distinct art unit to navigate the prosecution. The 1 pending office action represents the company's primary point of contact with the patent office for its current biotechnology filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698169 | N,N-DIMETHYL-4-(7-(N-(1-METHYLCYCLOPROPYL)SULFAMOYL)-IMIDAZO[1,5-A]PYRIDIN-5-YL)PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | YOO, SUN JAE | 1621 | §112 | Non-Final OA | — | Pending | Apr 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial